Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Results from London Regional Clinical Genetics services over a 5-year period on germline TP53 testing in women diagnosed with breast cancer at <30 years.

Journal of medical genetics - 1 Jun 2022

Garrett Alice, Talukdar Sabrina, Izatt Louise, Brady Angela F, Whyte Sinead, Josephs Katherine S, Shanmugasundaram Monisha, Guillemot Li Shan, Vakili Dara, Ey Shevaun, Ahmed Munaza

Abstract excerpt

BACKGROUND: The most common cancer diagnosed in germline TP53 pathogenic variant (PV) carriers is premenopausal breast cancer. An increased rate of breast tumour HER2 positivity has been reported in this group. Screening for breast/other cancers is recommended in PV carriers. OBJECTIVES: 1. To assess the frequency of germline TP53 PVs reported diagnostically in women with breast cancer at <30 years of age.2. To...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Breast Neoplasms
Share to Genetic Predisposition to Disease

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genetic Testing

Share to Germ Cells

Share to Germ-Line Mutation

Share to London

Share to Tumor Suppressor Protein p53

Source

Identifiers

PMID: 34266904
DOI: 10.1136/jmedgenet-2021-107742

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Results from London Regional Clinical Genetics services over a 5-year period on germline TP53 testing in women diagnosed with breast cancer at <30 years.PMID 34266904Read ↗

Utility of Expedited Hereditary Cancer Testing in the Surgical Management of Patients with a New Breast Cancer Diagnosis.Semantic proximity Read ↗

Identification and Management of Pathogenic Variants in BRCA1, BRCA2, and PALB2 in a Tumor-Only Genomic Testing Program.Semantic proximity Read ↗

Racial and Ethnic Differences in BRCA1/2 and Multigene Panel Testing Among Young Breast Cancer Patients.Semantic proximity Read ↗

Molecular characteristics of breast tumors in patients screened for germline predisposition from a population-based observational study.Semantic proximity Read ↗

Genetic testing women with newly diagnosed breast cancer: What criteria are the most predictive of a positive test?Semantic proximity Read ↗

Update: variable implementation of the 2018 UKCGG/UKGTN guidelines for breast cancer gene panel tests offered by UK genetics services.Semantic proximity Read ↗

Germline TP53 pathogenic variants and breast cancer: A narrative review.Semantic proximity Read ↗

Clinicopathological Characteristics and Treatment Outcomes in Breast Cancer in Women Under 50: A Real-World UK Cohort StudySemantic proximity Read ↗

Clinical Behavior of Breast Cancer in Young BRCA Carriers and Prediagnostic Awareness of Germline BRCA Status.Semantic proximity Read ↗

Germline testing for breast cancer patients in England: illogical to prioritise grade 1 breast cancer aged 30-39 over grade 3 aged 40-49 years?Semantic proximity Read ↗

Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing.Semantic proximity Read ↗

Genetic testing in a cohort of young patients with HER2-amplified breast cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.